by - A) Market Overview:
The India Active Pharmaceutical Ingredients (API) market is projected to reach a value of US$19,993.2 million in 2021, with an estimated compound annual growth rate (CAGR) of 8.3% from 2021 to 2028. APIs are essential components of pharmaceutical products, serving as the active substances that provide therapeutic effects. They are necessary for the formulation of various drugs, making them a crucial part of the healthcare industry.APIs offer several advantages, including enhanced drug efficacy, targeted drug delivery, and reduced side effects. They play a crucial role in the pharmaceutical manufacturing process, ensuring the quality, safety, and effectiveness of drugs. With the rising demand for generic drugs and the increasing focus on research and development activities, the API market in India is witnessing significant growth.
B) Market Key Trends:
One key trend prevailing in the India API market is the increased outsourcing of API production to India by global pharmaceutical companies. This trend can be attributed to India’s cost competitiveness, high production capacity, and proficiency in API production. As a result, international pharmaceutical companies are partnering with Indian API manufacturers to meet the growing demand for APIs.
For instance, Teva Pharmaceutical Industries Ltd., a global pharmaceutical company, has partnered with Indian API manufacturers for the production of active pharmaceutical ingredients. This collaboration has allowed Teva to streamline its supply chain and reduce manufacturing costs, ensuring enhanced product accessibility and affordability.
C) Porter’s Analysis:
Threat of new entrants: The threat of new entrants in the India API market is relatively low due to the high capital investment required, stringent regulatory requirements, and established market players’ dominance.
Bargaining power of buyers: The bargaining power of buyers is moderate as they have the option to choose among several established API manufacturers, resulting in intensified competition and pricing pressure.
Bargaining power of suppliers: The bargaining power of suppliers is high due to the limited number of suppliers offering high-quality APIs. This allows them to negotiate favorable terms and conditions with pharmaceutical companies.
Threat of new substitutes: The threat of substitutes is low as APIs are essential components in the pharmaceutical manufacturing process, and there are limited alternatives available.
Competitive rivalry: The competitive rivalry in the India Active Pharmaceutical Ingredients Market is intense, with several key players vying for market share. This competition fosters innovation and drives companies to enhance product quality and efficiency.
D) Key Takeaways:
In terms of market size, the India API market is poised for substantial growth, demonstrating an expected CAGR of 8.3% over the forecast period. This growth can be attributed to the increasing demand for generic drugs and the growing emphasis on research and development activities in the pharmaceutical sector.
Regionally, India has emerged as one of the fastest-growing and dominating regions in the API market. The country offers cost competitiveness, a vast pool of skilled labor, and a favorable regulatory environment, attracting global pharmaceutical companies to establish production facilities.
Key players operating in the India API market include Teva Pharmaceutical Industries Ltd., Salora, Aurobindo Pharma Limited, Dr. Reddy’s Laboratories, Lupin Limited, and Sun Pharmaceutical Industries Limited. These industry giants leverage their expertise and capabilities to produce high-quality APIs, meeting the demand of both domestic and global markets.
In summary, the India API market presents significant growth opportunities driven by rising demand for generic drugs, increasing outsourcing partnerships, and the country’s strong manufacturing capabilities. With the involvement of key players and advancements in research and development activities, the market is expected to flourish in the coming years.
